ReviewMetabolic brain disease2026
The role of gut dysbiosis in Parkinson's disease: pathophysiology, epidemiology, and emerging therapeutic strategies.
Review in Metabolic brain disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson’s disease (PD) is a prevalent neurodegenerative disorder characterized by the progressive loss of dopaminergic neurons in the substantia nigra, leading to motor and non-motor symptoms. While the underlying pathobiology remains incompletely understood, emerging evidence suggests a pivotal role for neuroinflammation, microglial activation, and misfolded α-synuclein aggregates. Recent research has highlighted gut dysbiosis as a contributing factor in PD pathology, with potential implications for disease onset and progression. Recent studies suggest that gut dysbiosis may influence PD onset and progression, highlighting the gut-brain axis as a critical mechanistic link. This review explores epidemiology, molecular etiology, genetic predispositions, and risk factors associated with PD, with particular emphasis on the role of gut microbiota. Furthermore, we discuss emerging gut-targeted therapeutic strategies, including probiotics, dietary interventions, and fecal microbiota transplantation (FMT), and their potential in mitigating PD pathology. Addressing gut dysbiosis may offer novel therapeutic avenues for early intervention and disease modification in PD.
Indexed as
Identifiers
41718784What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.